Intellia Therapeutics Gene Editing Product NTLA-2001 – A Dream on its Way to Becoming Reality

Focus on Intellia Therapeutics Upcoming Presentation for NTLA-2001

  • Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate
  • Late-breaking abstract selected for oral presentation on June 26

Intellia Therapeutics NTLA-2001 for People Living with hATTR-PN
Intellia Therapeutics (NTLA) announced that Phase 1 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.